Aprogen Biologics Inc. Logo

Aprogen Biologics Inc.

Develops and manufactures novel biologic drugs and biosimilars for the professional market.

003060 | KO

Overview

Corporate Details

ISIN(s):
KR7003060001
LEI:
Country:
South Korea
Address:
서울특별시 송파구 백제고분로 480 4층 (방이동, 풍문빌딩), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprogen Biologics Inc. is a biopharmaceutical company specializing in the research, development, and manufacturing of advanced biologic medicines. Founded in 2000, the company leverages proprietary technologies in antibody and recombinant protein engineering to create a pipeline of both novel drugs and biosimilars. Its portfolio is focused on developing biosimilar products for various major biologics, including infliximab, trastuzumab, and rituximab, alongside a range of novel drug candidates. The company aims to provide innovative and accessible medicines for the professional medication market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 100.6 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.0 MB
2025-08-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 102.1 KB
2025-05-30 00:00
Governance Information
기업지배구조보고서공시
Korean 639.1 KB
2025-05-26 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 67.8 KB
2025-05-26 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 17.7 KB
2025-05-22 00:00
Related Party Transaction
타법인주식및출자증권처분결정
Korean 16.0 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 3.2 MB
2025-05-07 00:00
Related Party Transaction
[기재정정]임원ㆍ주요주주특정증권등거래계획보고서
Korean 73.8 KB
2025-05-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.2 KB
2025-05-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-04-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 94.2 KB
2025-04-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-04-25 00:00
Capital/Financing Update
주권관련사채권의처분결정
Korean 16.4 KB
2025-04-11 00:00
Capital/Financing Update
타인에대한담보제공결정
Korean 15.7 KB

Automate Your Workflow. Get a real-time feed of all Aprogen Biologics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprogen Biologics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprogen Biologics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.